Eisai Expands Leadership Team

Eisai Inc. has expanded its leadership team to include two key appointments in the areas of Corporate Affairs and Market Access.

Joel W. Beetsch of Eisai

Joel W. Beetsch, Ph.D., joins the company as vice president, Corporate Affairs with more than 20 years of experience in the pharmaceutical industry, most recently as vice president, Corporate Affairs/Patient Advocacy at Celgene Corp. Dr. Beetsch will be responsible for cultivating and maintaining Eisai’s corporate reputation through strategic communications, government affairs, public policy and corporate advocacy.

 

Scott R. Steuart of Eisai

Scott R. Steuart joins Eisai as vice president, Market Access. Mr. Steuart has devoted his career to the pharmaceutical industry, serving in senior leadership roles at Sanofi and Pfizer, including 10 years leading Market Access organizations. Mr. Steuart will be responsible for setting the company’s vision and strategy to ensure patients have access to Eisai’s medicines within the company’s Neurology and Oncology portfolios.

These appointments follow two recent FDA approvals, and several additional marketing approval regulatory filings expected in 2020. Within the Eisai Oncology Business Group, the company has initiated 11 registrational trials for indications in seven types of cancer under another strategic collaboration, with two more trials planned to open this fiscal year.

“We welcome Joel and Scott to our leadership team. Building our organization in Corporate Affairs and Market Access will strengthen our role in the marketplace, and reinforce our commitment to serving the health care needs of patients and their families, which is our human health care mission,” said Tatsuyuki Yasuno, president, Eisai Inc. “We are on the verge of unprecedented growth, and there has never been a more exciting time to join Eisai Inc.”